nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP1A1—chronic obstructive pulmonary disease	0.175	0.36	CbGaD
Haloperidol—CYP1A2—chronic obstructive pulmonary disease	0.169	0.347	CbGaD
Haloperidol—HTR2A—chronic obstructive pulmonary disease	0.143	0.293	CbGaD
Haloperidol—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0279	0.0938	CbGbCtD
Haloperidol—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0279	0.0938	CbGbCtD
Haloperidol—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0232	0.078	CbGbCtD
Haloperidol—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0232	0.078	CbGbCtD
Haloperidol—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0219	0.0736	CbGbCtD
Haloperidol—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0212	0.0713	CbGbCtD
Haloperidol—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0212	0.0713	CbGbCtD
Haloperidol—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0189	0.0636	CbGbCtD
Haloperidol—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0178	0.0599	CbGbCtD
Haloperidol—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0176	0.0591	CbGbCtD
Haloperidol—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.012	0.0404	CbGbCtD
Haloperidol—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0117	0.0394	CbGbCtD
Haloperidol—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0115	0.0386	CbGbCtD
Haloperidol—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0102	0.0344	CbGbCtD
Haloperidol—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.01	0.0337	CbGbCtD
Haloperidol—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00945	0.0318	CbGbCtD
Haloperidol—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.00611	0.22	CbGeAlD
Haloperidol—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.006	0.0202	CbGbCtD
Haloperidol—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00566	0.019	CbGbCtD
Haloperidol—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00222	0.0798	CbGeAlD
Haloperidol—CBR1—respiratory system—chronic obstructive pulmonary disease	0.00118	0.0426	CbGeAlD
Haloperidol—CBR1—bronchus—chronic obstructive pulmonary disease	0.000975	0.035	CbGeAlD
Haloperidol—H1F0—respiratory system—chronic obstructive pulmonary disease	0.00097	0.0349	CbGeAlD
Haloperidol—CBR1—trachea—chronic obstructive pulmonary disease	0.000875	0.0315	CbGeAlD
Haloperidol—H1F0—connective tissue—chronic obstructive pulmonary disease	0.000854	0.0307	CbGeAlD
Haloperidol—H1F0—bronchus—chronic obstructive pulmonary disease	0.000799	0.0287	CbGeAlD
Haloperidol—H1F0—smooth muscle tissue—chronic obstructive pulmonary disease	0.000781	0.0281	CbGeAlD
Haloperidol—H1F0—trachea—chronic obstructive pulmonary disease	0.000717	0.0258	CbGeAlD
Haloperidol—HTR1D—connective tissue—chronic obstructive pulmonary disease	0.000662	0.0238	CbGeAlD
Haloperidol—Moclobemide—CYP1A2—chronic obstructive pulmonary disease	0.000651	0.182	CrCbGaD
Haloperidol—Droperidol—HTR2A—chronic obstructive pulmonary disease	0.000646	0.181	CrCbGaD
Haloperidol—CBR1—lung—chronic obstructive pulmonary disease	0.000629	0.0226	CbGeAlD
Haloperidol—SIGMAR1—bronchus—chronic obstructive pulmonary disease	0.000577	0.0207	CbGeAlD
Haloperidol—DRD2—respiratory system—chronic obstructive pulmonary disease	0.000566	0.0203	CbGeAlD
Haloperidol—SIGMAR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000564	0.0203	CbGeAlD
Haloperidol—HTR2B—smooth muscle tissue—chronic obstructive pulmonary disease	0.000563	0.0202	CbGeAlD
Haloperidol—Mazindol—SLC6A4—chronic obstructive pulmonary disease	0.000542	0.151	CrCbGaD
Haloperidol—Sertindole—SLC6A4—chronic obstructive pulmonary disease	0.000542	0.151	CrCbGaD
Haloperidol—SIGMAR1—trachea—chronic obstructive pulmonary disease	0.000518	0.0186	CbGeAlD
Haloperidol—H1F0—lung—chronic obstructive pulmonary disease	0.000515	0.0185	CbGeAlD
Haloperidol—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000478	0.0172	CbGeAlD
Haloperidol—CYP1A1—respiratory system—chronic obstructive pulmonary disease	0.000471	0.0169	CbGeAlD
Haloperidol—CYP3A5—respiratory system—chronic obstructive pulmonary disease	0.000461	0.0166	CbGeAlD
Haloperidol—HRH1—respiratory system—chronic obstructive pulmonary disease	0.000447	0.0161	CbGeAlD
Haloperidol—Fluspirilene—SLC6A4—chronic obstructive pulmonary disease	0.000442	0.123	CrCbGaD
Haloperidol—Sertindole—HTR2A—chronic obstructive pulmonary disease	0.000417	0.116	CrCbGaD
Haloperidol—HRH1—connective tissue—chronic obstructive pulmonary disease	0.000393	0.0141	CbGeAlD
Haloperidol—CYP1A1—bronchus—chronic obstructive pulmonary disease	0.000388	0.0139	CbGeAlD
Haloperidol—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.000373	0.0134	CbGeAlD
Haloperidol—SIGMAR1—lung—chronic obstructive pulmonary disease	0.000372	0.0134	CbGeAlD
Haloperidol—HTR2B—lung—chronic obstructive pulmonary disease	0.000371	0.0133	CbGeAlD
Haloperidol—HRH1—smooth muscle tissue—chronic obstructive pulmonary disease	0.00036	0.0129	CbGeAlD
Haloperidol—CYP1A1—trachea—chronic obstructive pulmonary disease	0.000348	0.0125	CbGeAlD
Haloperidol—Fluspirilene—HTR2A—chronic obstructive pulmonary disease	0.00034	0.0949	CrCbGaD
Haloperidol—HRH1—trachea—chronic obstructive pulmonary disease	0.00033	0.0119	CbGeAlD
Haloperidol—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000329	0.0118	CbGeAlD
Haloperidol—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000301	0.0108	CbGeAlD
Haloperidol—DRD2—lung—chronic obstructive pulmonary disease	0.000301	0.0108	CbGeAlD
Haloperidol—Amenorrhoea—Prednisone—chronic obstructive pulmonary disease	0.000295	0.00274	CcSEcCtD
Haloperidol—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000294	0.00273	CcSEcCtD
Haloperidol—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000294	0.00273	CcSEcCtD
Haloperidol—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000292	0.00272	CcSEcCtD
Haloperidol—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000292	0.00271	CcSEcCtD
Haloperidol—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000292	0.00271	CcSEcCtD
Haloperidol—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000291	0.00271	CcSEcCtD
Haloperidol—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000291	0.0027	CcSEcCtD
Haloperidol—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00029	0.00269	CcSEcCtD
Haloperidol—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.00029	0.00269	CcSEcCtD
Haloperidol—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00029	0.00269	CcSEcCtD
Haloperidol—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00029	0.00269	CcSEcCtD
Haloperidol—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000288	0.00268	CcSEcCtD
Haloperidol—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.00267	CcSEcCtD
Haloperidol—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000288	0.00267	CcSEcCtD
Haloperidol—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000285	0.00265	CcSEcCtD
Haloperidol—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000284	0.00264	CcSEcCtD
Haloperidol—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.000284	0.00263	CcSEcCtD
Haloperidol—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.000283	0.00263	CcSEcCtD
Haloperidol—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000283	0.00263	CcSEcCtD
Haloperidol—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.00262	CcSEcCtD
Haloperidol—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.00261	CcSEcCtD
Haloperidol—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000279	0.00259	CcSEcCtD
Haloperidol—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000277	0.00257	CcSEcCtD
Haloperidol—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000277	0.00257	CcSEcCtD
Haloperidol—HTR2A—trachea—chronic obstructive pulmonary disease	0.000276	0.00992	CbGeAlD
Haloperidol—Leukocytosis—Prednisone—chronic obstructive pulmonary disease	0.000276	0.00256	CcSEcCtD
Haloperidol—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000275	0.00255	CcSEcCtD
Haloperidol—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00254	CcSEcCtD
Haloperidol—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000273	0.00254	CcSEcCtD
Haloperidol—Cataract—Prednisone—chronic obstructive pulmonary disease	0.000272	0.00253	CcSEcCtD
Haloperidol—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00252	CcSEcCtD
Haloperidol—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000272	0.00252	CcSEcCtD
Haloperidol—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00252	CcSEcCtD
Haloperidol—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.00027	0.0025	CcSEcCtD
Haloperidol—Tremor—Formoterol—chronic obstructive pulmonary disease	0.00027	0.0025	CcSEcCtD
Haloperidol—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000268	0.00249	CcSEcCtD
Haloperidol—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000264	0.00246	CcSEcCtD
Haloperidol—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000264	0.00246	CcSEcCtD
Haloperidol—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00245	CcSEcCtD
Haloperidol—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000263	0.00244	CcSEcCtD
Haloperidol—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00243	CcSEcCtD
Haloperidol—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000259	0.00241	CcSEcCtD
Haloperidol—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000256	0.00238	CcSEcCtD
Haloperidol—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000255	0.00236	CcSEcCtD
Haloperidol—CYP1A2—lung—chronic obstructive pulmonary disease	0.000254	0.00911	CbGeAlD
Haloperidol—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000251	0.00233	CcSEcCtD
Haloperidol—CYP1A1—lung—chronic obstructive pulmonary disease	0.00025	0.00899	CbGeAlD
Haloperidol—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.00025	0.00232	CcSEcCtD
Haloperidol—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000249	0.00231	CcSEcCtD
Haloperidol—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00231	CcSEcCtD
Haloperidol—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00231	CcSEcCtD
Haloperidol—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000246	0.00229	CcSEcCtD
Haloperidol—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000245	0.00228	CcSEcCtD
Haloperidol—ABCB1—respiratory system—chronic obstructive pulmonary disease	0.000245	0.0088	CbGeAlD
Haloperidol—CYP3A5—lung—chronic obstructive pulmonary disease	0.000245	0.00879	CbGeAlD
Haloperidol—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000244	0.00227	CcSEcCtD
Haloperidol—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000244	0.00227	CcSEcCtD
Haloperidol—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000244	0.00227	CcSEcCtD
Haloperidol—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000244	0.00227	CcSEcCtD
Haloperidol—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000244	0.00227	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000243	0.00226	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000243	0.00226	CcSEcCtD
Haloperidol—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00223	CcSEcCtD
Haloperidol—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00223	CcSEcCtD
Haloperidol—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000239	0.00222	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000238	0.00221	CcSEcCtD
Haloperidol—HRH1—lung—chronic obstructive pulmonary disease	0.000237	0.00853	CbGeAlD
Haloperidol—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00218	CcSEcCtD
Haloperidol—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00218	CcSEcCtD
Haloperidol—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000235	0.00218	CcSEcCtD
Haloperidol—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000235	0.00218	CcSEcCtD
Haloperidol—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00218	CcSEcCtD
Haloperidol—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000231	0.00215	CcSEcCtD
Haloperidol—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00023	0.00214	CcSEcCtD
Haloperidol—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.00214	CcSEcCtD
Haloperidol—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00023	0.00214	CcSEcCtD
Haloperidol—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00214	CcSEcCtD
Haloperidol—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00023	0.00214	CcSEcCtD
Haloperidol—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000229	0.00213	CcSEcCtD
Haloperidol—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000229	0.00213	CcSEcCtD
Haloperidol—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000228	0.00212	CcSEcCtD
Haloperidol—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000228	0.00212	CcSEcCtD
Haloperidol—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000227	0.00211	CcSEcCtD
Haloperidol—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000226	0.0021	CcSEcCtD
Haloperidol—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000226	0.0021	CcSEcCtD
Haloperidol—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000226	0.0021	CcSEcCtD
Haloperidol—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000225	0.00209	CcSEcCtD
Haloperidol—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000223	0.00208	CcSEcCtD
Haloperidol—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000223	0.00207	CcSEcCtD
Haloperidol—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00206	CcSEcCtD
Haloperidol—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000222	0.00206	CcSEcCtD
Haloperidol—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000219	0.00204	CcSEcCtD
Haloperidol—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000219	0.00204	CcSEcCtD
Haloperidol—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000218	0.00203	CcSEcCtD
Haloperidol—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000218	0.00202	CcSEcCtD
Haloperidol—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.00202	CcSEcCtD
Haloperidol—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.00201	CcSEcCtD
Haloperidol—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.002	CcSEcCtD
Haloperidol—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000214	0.00199	CcSEcCtD
Haloperidol—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.00199	CcSEcCtD
Haloperidol—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000212	0.00197	CcSEcCtD
Haloperidol—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000212	0.00197	CcSEcCtD
Haloperidol—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00196	CcSEcCtD
Haloperidol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00196	CcSEcCtD
Haloperidol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000209	0.00194	CcSEcCtD
Haloperidol—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000209	0.00194	CcSEcCtD
Haloperidol—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000209	0.00194	CcSEcCtD
Haloperidol—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000209	0.00194	CcSEcCtD
Haloperidol—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000208	0.00193	CcSEcCtD
Haloperidol—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.00192	CcSEcCtD
Haloperidol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00192	CcSEcCtD
Haloperidol—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00192	CcSEcCtD
Haloperidol—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000206	0.00191	CcSEcCtD
Haloperidol—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000204	0.0019	CcSEcCtD
Haloperidol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000204	0.0019	CcSEcCtD
Haloperidol—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000204	0.00189	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.00188	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000203	0.00188	CcSEcCtD
Haloperidol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000202	0.00188	CcSEcCtD
Haloperidol—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000201	0.00187	CcSEcCtD
Haloperidol—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000201	0.00187	CcSEcCtD
Haloperidol—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000201	0.00186	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000199	0.00184	CcSEcCtD
Haloperidol—HTR2A—lung—chronic obstructive pulmonary disease	0.000198	0.00713	CbGeAlD
Haloperidol—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000198	0.00184	CcSEcCtD
Haloperidol—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000197	0.00183	CcSEcCtD
Haloperidol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000196	0.00182	CcSEcCtD
Haloperidol—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00181	CcSEcCtD
Haloperidol—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000195	0.00181	CcSEcCtD
Haloperidol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000194	0.00181	CcSEcCtD
Haloperidol—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000193	0.0018	CcSEcCtD
Haloperidol—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000193	0.0018	CcSEcCtD
Haloperidol—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000193	0.0018	CcSEcCtD
Haloperidol—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000193	0.00179	CcSEcCtD
Haloperidol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000192	0.00179	CcSEcCtD
Haloperidol—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000192	0.00178	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000191	0.00178	CcSEcCtD
Haloperidol—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00019	0.00176	CcSEcCtD
Haloperidol—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000187	0.00173	CcSEcCtD
Haloperidol—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000187	0.00173	CcSEcCtD
Haloperidol—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00172	CcSEcCtD
Haloperidol—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00172	CcSEcCtD
Haloperidol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000185	0.00172	CcSEcCtD
Haloperidol—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000184	0.00171	CcSEcCtD
Haloperidol—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000183	0.0017	CcSEcCtD
Haloperidol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000183	0.0017	CcSEcCtD
Haloperidol—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000183	0.0017	CcSEcCtD
Haloperidol—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000183	0.0017	CcSEcCtD
Haloperidol—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.0017	CcSEcCtD
Haloperidol—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000182	0.00169	CcSEcCtD
Haloperidol—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00169	CcSEcCtD
Haloperidol—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000182	0.00169	CcSEcCtD
Haloperidol—ABCB1—trachea—chronic obstructive pulmonary disease	0.000181	0.0065	CbGeAlD
Haloperidol—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000179	0.00166	CcSEcCtD
Haloperidol—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000176	0.00164	CcSEcCtD
Haloperidol—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00163	CcSEcCtD
Haloperidol—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000173	0.00161	CcSEcCtD
Haloperidol—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000173	0.00161	CcSEcCtD
Haloperidol—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000173	0.00161	CcSEcCtD
Haloperidol—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000172	0.0016	CcSEcCtD
Haloperidol—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000169	0.00157	CcSEcCtD
Haloperidol—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000166	0.00154	CcSEcCtD
Haloperidol—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000166	0.00154	CcSEcCtD
Haloperidol—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000163	0.00152	CcSEcCtD
Haloperidol—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000163	0.00151	CcSEcCtD
Haloperidol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00149	CcSEcCtD
Haloperidol—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00149	CcSEcCtD
Haloperidol—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000158	0.00147	CcSEcCtD
Haloperidol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000157	0.00146	CcSEcCtD
Haloperidol—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000157	0.00146	CcSEcCtD
Haloperidol—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000155	0.00144	CcSEcCtD
Haloperidol—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000155	0.00144	CcSEcCtD
Haloperidol—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000152	0.00141	CcSEcCtD
Haloperidol—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00141	CcSEcCtD
Haloperidol—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00141	CcSEcCtD
Haloperidol—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.00015	0.00139	CcSEcCtD
Haloperidol—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000149	0.00139	CcSEcCtD
Haloperidol—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000149	0.00139	CcSEcCtD
Haloperidol—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000148	0.00138	CcSEcCtD
Haloperidol—Rash—Formoterol—chronic obstructive pulmonary disease	0.000148	0.00138	CcSEcCtD
Haloperidol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000148	0.00137	CcSEcCtD
Haloperidol—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000148	0.00137	CcSEcCtD
Haloperidol—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000148	0.00137	CcSEcCtD
Haloperidol—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000147	0.00137	CcSEcCtD
Haloperidol—Headache—Formoterol—chronic obstructive pulmonary disease	0.000147	0.00137	CcSEcCtD
Haloperidol—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000147	0.00137	CcSEcCtD
Haloperidol—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.00136	CcSEcCtD
Haloperidol—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000147	0.00136	CcSEcCtD
Haloperidol—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000147	0.00136	CcSEcCtD
Haloperidol—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000146	0.00136	CcSEcCtD
Haloperidol—Rash—Montelukast—chronic obstructive pulmonary disease	0.000145	0.00135	CcSEcCtD
Haloperidol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000145	0.00135	CcSEcCtD
Haloperidol—Depression—Prednisone—chronic obstructive pulmonary disease	0.000144	0.00134	CcSEcCtD
Haloperidol—Headache—Montelukast—chronic obstructive pulmonary disease	0.000144	0.00134	CcSEcCtD
Haloperidol—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000141	0.00131	CcSEcCtD
Haloperidol—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.0013	CcSEcCtD
Haloperidol—Rash—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.0013	CcSEcCtD
Haloperidol—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.00014	0.0013	CcSEcCtD
Haloperidol—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000139	0.0013	CcSEcCtD
Haloperidol—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000139	0.0013	CcSEcCtD
Haloperidol—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000139	0.00129	CcSEcCtD
Haloperidol—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000137	0.00127	CcSEcCtD
Haloperidol—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.00125	CcSEcCtD
Haloperidol—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000135	0.00125	CcSEcCtD
Haloperidol—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000132	0.00122	CcSEcCtD
Haloperidol—ABCB1—lung—chronic obstructive pulmonary disease	0.00013	0.00467	CbGeAlD
Haloperidol—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000129	0.0012	CcSEcCtD
Haloperidol—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000128	0.00119	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.00118	CcSEcCtD
Haloperidol—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000127	0.00118	CcSEcCtD
Haloperidol—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.00115	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000123	0.00114	CcSEcCtD
Haloperidol—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000122	0.00113	CcSEcCtD
Haloperidol—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000118	0.0011	CcSEcCtD
Haloperidol—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000117	0.00109	CcSEcCtD
Haloperidol—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000115	0.00107	CcSEcCtD
Haloperidol—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000115	0.00107	CcSEcCtD
Haloperidol—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000114	0.00106	CcSEcCtD
Haloperidol—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000113	0.00105	CcSEcCtD
Haloperidol—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000991	CcSEcCtD
Haloperidol—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000105	0.000973	CcSEcCtD
Haloperidol—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000972	CcSEcCtD
Haloperidol—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000966	CcSEcCtD
Haloperidol—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000945	CcSEcCtD
Haloperidol—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000938	CcSEcCtD
Haloperidol—Convulsion—Prednisone—chronic obstructive pulmonary disease	9.81e-05	0.000911	CcSEcCtD
Haloperidol—Hypertension—Prednisone—chronic obstructive pulmonary disease	9.78e-05	0.000908	CcSEcCtD
Haloperidol—Anxiety—Prednisone—chronic obstructive pulmonary disease	9.61e-05	0.000892	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	9.57e-05	0.000889	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	9.37e-05	0.00087	CcSEcCtD
Haloperidol—Oedema—Prednisone—chronic obstructive pulmonary disease	9.24e-05	0.000858	CcSEcCtD
Haloperidol—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	9.24e-05	0.000858	CcSEcCtD
Haloperidol—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000842	CcSEcCtD
Haloperidol—Tachycardia—Prednisone—chronic obstructive pulmonary disease	9.02e-05	0.000838	CcSEcCtD
Haloperidol—Skin disorder—Prednisone—chronic obstructive pulmonary disease	8.98e-05	0.000834	CcSEcCtD
Haloperidol—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	8.93e-05	0.00083	CcSEcCtD
Haloperidol—Anorexia—Prednisone—chronic obstructive pulmonary disease	8.81e-05	0.000818	CcSEcCtD
Haloperidol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	8.41e-05	0.000781	CcSEcCtD
Haloperidol—Insomnia—Prednisone—chronic obstructive pulmonary disease	8.36e-05	0.000776	CcSEcCtD
Haloperidol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	8.13e-05	0.000756	CcSEcCtD
Haloperidol—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	8.03e-05	0.000746	CcSEcCtD
Haloperidol—Rash—Prednisolone—chronic obstructive pulmonary disease	8.02e-05	0.000745	CcSEcCtD
Haloperidol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	8.01e-05	0.000744	CcSEcCtD
Haloperidol—Headache—Prednisolone—chronic obstructive pulmonary disease	7.97e-05	0.00074	CcSEcCtD
Haloperidol—Constipation—Prednisone—chronic obstructive pulmonary disease	7.9e-05	0.000734	CcSEcCtD
Haloperidol—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	7.61e-05	0.000707	CcSEcCtD
Haloperidol—Nausea—Prednisolone—chronic obstructive pulmonary disease	7.55e-05	0.000702	CcSEcCtD
Haloperidol—Urticaria—Prednisone—chronic obstructive pulmonary disease	7.34e-05	0.000682	CcSEcCtD
Haloperidol—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	7.3e-05	0.000679	CcSEcCtD
Haloperidol—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	6.81e-05	0.000632	CcSEcCtD
Haloperidol—Pruritus—Prednisone—chronic obstructive pulmonary disease	6.54e-05	0.000607	CcSEcCtD
Haloperidol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	6.32e-05	0.000587	CcSEcCtD
Haloperidol—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.11e-05	0.000568	CcSEcCtD
Haloperidol—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.88e-05	0.000546	CcSEcCtD
Haloperidol—Rash—Prednisone—chronic obstructive pulmonary disease	5.83e-05	0.000541	CcSEcCtD
Haloperidol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.82e-05	0.000541	CcSEcCtD
Haloperidol—Headache—Prednisone—chronic obstructive pulmonary disease	5.79e-05	0.000538	CcSEcCtD
Haloperidol—Nausea—Prednisone—chronic obstructive pulmonary disease	5.49e-05	0.00051	CcSEcCtD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.91e-06	0.000129	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	9.91e-06	0.000129	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.81e-06	0.000128	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	9.8e-06	0.000128	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	9.69e-06	0.000126	CbGpPWpGaD
Haloperidol—HTR2B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.64e-06	0.000126	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.57e-06	0.000125	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.52e-06	0.000124	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.46e-06	0.000123	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	9.36e-06	0.000122	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.32e-06	0.000121	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.26e-06	0.000121	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	9.17e-06	0.000119	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.14e-06	0.000119	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	9.11e-06	0.000119	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	9.1e-06	0.000118	CbGpPWpGaD
Haloperidol—DRD1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.09e-06	0.000118	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.07e-06	0.000118	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.03e-06	0.000118	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.02e-06	0.000117	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	9e-06	0.000117	CbGpPWpGaD
Haloperidol—DRD3—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	8.97e-06	0.000117	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.91e-06	0.000116	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.9e-06	0.000116	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.89e-06	0.000116	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	8.84e-06	0.000115	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	8.83e-06	0.000115	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.77e-06	0.000114	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.75e-06	0.000114	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.74e-06	0.000114	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	8.72e-06	0.000114	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.7e-06	0.000113	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.66e-06	0.000113	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.62e-06	0.000112	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	8.47e-06	0.00011	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.46e-06	0.00011	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.37e-06	0.000109	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.28e-06	0.000108	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.26e-06	0.000108	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.26e-06	0.000107	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.21e-06	0.000107	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.2e-06	0.000107	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—LEP—chronic obstructive pulmonary disease	8.15e-06	0.000106	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.15e-06	0.000106	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.14e-06	0.000106	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.13e-06	0.000106	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.11e-06	0.000106	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.09e-06	0.000105	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.02e-06	0.000104	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	7.93e-06	0.000103	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.89e-06	0.000103	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.83e-06	0.000102	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.79e-06	0.000101	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.78e-06	0.000101	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	7.74e-06	0.000101	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.62e-06	9.93e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.5e-06	9.77e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	7.49e-06	9.75e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.39e-06	9.62e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.38e-06	9.6e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.34e-06	9.56e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.31e-06	9.52e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	7.29e-06	9.49e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.24e-06	9.43e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	7.23e-06	9.42e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	7.23e-06	9.41e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.19e-06	9.36e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.09e-06	9.23e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.06e-06	9.19e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—ALB—chronic obstructive pulmonary disease	7e-06	9.12e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.96e-06	9.06e-05	CbGpPWpGaD
Haloperidol—DRD2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.86e-06	8.94e-05	CbGpPWpGaD
Haloperidol—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	6.86e-06	8.93e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.81e-06	8.87e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.81e-06	8.87e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	6.79e-06	8.84e-05	CbGpPWpGaD
Haloperidol—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.75e-06	8.79e-05	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.74e-06	8.77e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.74e-06	8.77e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.7e-06	8.73e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.7e-06	8.73e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.7e-06	8.72e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—NOS3—chronic obstructive pulmonary disease	6.7e-06	8.72e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.69e-06	8.71e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.66e-06	8.68e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	6.65e-06	8.66e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.64e-06	8.64e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.61e-06	8.6e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	6.6e-06	8.59e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.5e-06	8.47e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.5e-06	8.46e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.4e-06	8.33e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.4e-06	8.33e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.34e-06	8.25e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.26e-06	8.15e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.25e-06	8.14e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.24e-06	8.13e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.23e-06	8.12e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.21e-06	8.08e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.19e-06	8.06e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	6.18e-06	8.04e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.13e-06	7.99e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.13e-06	7.98e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.12e-06	7.97e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	6.11e-06	7.95e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.11e-06	7.95e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.09e-06	7.93e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.08e-06	7.92e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.08e-06	7.91e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.03e-06	7.86e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.96e-06	7.76e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.95e-06	7.75e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	5.89e-06	7.67e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.85e-06	7.62e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.83e-06	7.59e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.76e-06	7.5e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.76e-06	7.5e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.68e-06	7.4e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	5.64e-06	7.34e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	5.63e-06	7.34e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.62e-06	7.32e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.56e-06	7.24e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.54e-06	7.21e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.51e-06	7.17e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.5e-06	7.16e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.48e-06	7.14e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.45e-06	7.1e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.44e-06	7.08e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.43e-06	7.06e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.42e-06	7.06e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.42e-06	7.05e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.35e-06	6.97e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.35e-06	6.96e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.24e-06	6.82e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.17e-06	6.73e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	5.15e-06	6.71e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.11e-06	6.66e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.11e-06	6.65e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.09e-06	6.62e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.07e-06	6.6e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.04e-06	6.56e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5e-06	6.51e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.99e-06	6.49e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.98e-06	6.48e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.92e-06	6.4e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.9e-06	6.38e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.88e-06	6.35e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.84e-06	6.3e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.82e-06	6.28e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.81e-06	6.27e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	4.77e-06	6.21e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.73e-06	6.15e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.7e-06	6.12e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.68e-06	6.09e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.66e-06	6.06e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.64e-06	6.04e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.58e-06	5.96e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.57e-06	5.95e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.56e-06	5.93e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.48e-06	5.84e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.47e-06	5.82e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.47e-06	5.82e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.45e-06	5.8e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.42e-06	5.75e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.41e-06	5.74e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.4e-06	5.73e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.35e-06	5.67e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.35e-06	5.66e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.35e-06	5.66e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.33e-06	5.64e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.28e-06	5.57e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.27e-06	5.56e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.27e-06	5.56e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	4.26e-06	5.54e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.2e-06	5.47e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.19e-06	5.46e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.15e-06	5.4e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.11e-06	5.35e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.1e-06	5.34e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.08e-06	5.32e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.08e-06	5.31e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	4.07e-06	5.3e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.04e-06	5.26e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.02e-06	5.24e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	4.02e-06	5.24e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.01e-06	5.22e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.98e-06	5.18e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.96e-06	5.16e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.96e-06	5.16e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.91e-06	5.09e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.86e-06	5.02e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.85e-06	5.01e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.78e-06	4.92e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.77e-06	4.91e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.68e-06	4.79e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.64e-06	4.73e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.62e-06	4.72e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.62e-06	4.71e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.59e-06	4.67e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.56e-06	4.64e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.52e-06	4.58e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.5e-06	4.56e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.45e-06	4.49e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.45e-06	4.49e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.44e-06	4.48e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.38e-06	4.4e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.34e-06	4.35e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.33e-06	4.34e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.32e-06	4.33e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.3e-06	4.29e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	3.29e-06	4.29e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.28e-06	4.27e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.27e-06	4.26e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.21e-06	4.18e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.17e-06	4.13e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.16e-06	4.11e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	3.15e-06	4.1e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.09e-06	4.03e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.07e-06	4e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.07e-06	4e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.04e-06	3.96e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.03e-06	3.94e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3e-06	3.91e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.99e-06	3.9e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.99e-06	3.89e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.95e-06	3.84e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.94e-06	3.83e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.94e-06	3.82e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.91e-06	3.79e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.91e-06	3.78e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.9e-06	3.77e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.87e-06	3.74e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.74e-06	3.57e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.74e-06	3.57e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.7e-06	3.52e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.7e-06	3.52e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.7e-06	3.51e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.69e-06	3.5e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.65e-06	3.45e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.64e-06	3.44e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.56e-06	3.34e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.45e-06	3.19e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.26e-06	2.94e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.22e-06	2.89e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.22e-06	2.89e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.07e-06	2.69e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.04e-06	2.65e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.03e-06	2.64e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.98e-06	2.58e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.89e-06	2.47e-05	CbGpPWpGaD
